Athira Pharma Stock Forecast, Price & News

+0.15 (+1.51 %)
(As of 08/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume302,153 shs
Average Volume752,439 shs
Market Capitalization$374.46 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ATHA News and Ratings via Email

Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter.

Athira Pharma logo

About Athira Pharma

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.20 out of 5 stars

Medical Sector

341st out of 1,309 stocks

Biological Products, Except Diagnostic Industry

51st out of 179 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Athira Pharma (NASDAQ:ATHA) Frequently Asked Questions

Is Athira Pharma a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athira Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Athira Pharma stock.
View analyst ratings for Athira Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Athira Pharma?

Wall Street analysts have given Athira Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Athira Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Athira Pharma?

Athira Pharma saw a decrease in short interest during the month of June. As of June 30th, there was short interest totaling 1,210,000 shares, a decrease of 28.4% from the June 15th total of 1,690,000 shares. Based on an average daily trading volume, of 1,120,000 shares, the days-to-cover ratio is presently 1.1 days. Approximately 3.6% of the company's stock are short sold.
View Athira Pharma's Short Interest

When is Athira Pharma's next earnings date?

Athira Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Athira Pharma

How were Athira Pharma's earnings last quarter?

Athira Pharma, Inc. (NASDAQ:ATHA) released its quarterly earnings results on Wednesday, May, 12th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.05.
View Athira Pharma's earnings history

What price target have analysts set for ATHA?

4 brokerages have issued 12 month price objectives for Athira Pharma's stock. Their forecasts range from $30.00 to $53.00. On average, they anticipate Athira Pharma's stock price to reach $42.50 in the next twelve months. This suggests a possible upside of 322.5% from the stock's current price.
View analysts' price targets for Athira Pharma
or view top-rated stocks among Wall Street analysts.

Who are Athira Pharma's key executives?

Athira Pharma's management team includes the following people:
  • Dr. Leen Kawas, CEO, Pres & Director (Age 35, Pay $706.47k)
  • Ms. Glenna K. Mileson, CFO & Corp. Sec. (Age 62, Pay $417.64k)
  • Dr. Hans Moebius, Chief Medical Officer (Age 64, Pay $425.06k)
  • Dr. Mark J. Litton M.B.A., Ph.D., MBA, Chief Operating Officer (Age 53)
  • Mr. Robert Renninger, Director of Accounting & Reporting
  • Ms. Rachel P. Lenington, CTO & Head of Product Devel. Strategy
  • Mr. Mark F. Worthington, Gen. Counsel
  • Dr. Kevin Church Ph.D., VP of Discovery (Age 36)

Who are some of Athira Pharma's key competitors?

What other stocks do shareholders of Athira Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athira Pharma investors own include GW Pharmaceuticals (GWPH), Intel (INTC), Lumentum (LITE), NIO (NIO), NVIDIA (NVDA), The Boeing (BA), Alibaba Group (BABA), Beyond Meat (BYND), Delta Air Lines (DAL) and Extreme Networks (EXTR).

When did Athira Pharma IPO?

(ATHA) raised $160 million in an IPO on Friday, September 18th 2020. The company issued 10,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel acted as the underwriters for the IPO and JMP Securities was co-manager.

What is Athira Pharma's stock symbol?

Athira Pharma trades on the NASDAQ under the ticker symbol "ATHA."

Who are Athira Pharma's major shareholders?

Athira Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Advisor Group Holdings Inc. (0.35%), Alliancebernstein L.P. (0.15%), Ieq Capital LLC (0.13%), Lindbrook Capital LLC (0.11%), New York State Common Retirement Fund (0.07%) and Rothschild Investment Corp IL (0.06%). Company insiders that own Athira Pharma stock include Joseph Edelman and Perceptive Advisors Llc.
View institutional ownership trends for Athira Pharma

Which institutional investors are buying Athira Pharma stock?

ATHA stock was bought by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., Alliancebernstein L.P., Ieq Capital LLC, Rothschild Investment Corp IL, Lindbrook Capital LLC, Clear Creek Financial Management LLC, New York State Common Retirement Fund, and Cutler Group LP. Company insiders that have bought Athira Pharma stock in the last two years include Joseph Edelman, and Perceptive Advisors Llc.
View insider buying and selling activity for Athira Pharma
or or view top insider-buying stocks.

How do I buy shares of Athira Pharma?

Shares of ATHA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Athira Pharma's stock price today?

One share of ATHA stock can currently be purchased for approximately $10.06.

How much money does Athira Pharma make?

Athira Pharma has a market capitalization of $374.46 million. The company earns $-19,950,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis.

How many employees does Athira Pharma have?

Athira Pharma employs 20 workers across the globe.

What is Athira Pharma's official website?

The official website for Athira Pharma is

How can I contact Athira Pharma?

The company can be reached via phone at 206-221-8112 or via email at [email protected]

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.